Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) — The “Meningococcal Vaccine Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User and Region 2024-2032” report has been added to ResearchAndMarkets.com offerings.
The global meningococcal vaccine market size reached USD 3.6 billion in 2023. In the future, the market will reach USD 7.2 billion by 2032, exhibiting a CAGR of 8.01% during the period 2023-2032 .
The increasing prevalence of meningococcal disease among children and adolescents across the globe is one of the key factors driving the growth of the market. Additionally, increasing health awareness among the masses and adoption of routine immunization provides an impetus for the market growth. The meningococcal vaccine helps prevent the disease and minimize long-term effects such as temporary or permanent deafness, loss of vision and motor skills, seizures, and neurological damage.
In line with this, governments in both developed and emerging economies are launching extensive public health programmes, emphasizing the immunization of special risk groups such as tourists and military personnel, to limit the risks of infection. Additionally, various product innovations such as the development of ready-to-use liquid formulations that do not require reconstitution are also contributing to market growth. Other factors including extensive research and development (R&D) activities along with improvements in healthcare infrastructure are expected to drive the market further.
Key questions answered in this report:
- How has the global meningococcal vaccine market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global meningococcal vaccine market?
- What are the key regional markets?
- What is the market breakdown by vaccine type?
- What is the breakdown of the market based on composition?
- What is the market breakdown by vaccine serotype?
- What is the market breakdown based on distribution channel?
- What is the market breakdown by end user?
- What are the different stages in the industry value chain?
- What are the key drivers and challenges in the industry?
- What is the structure of the global meningococcal vaccine market and who are the key players?
- What is the degree of competition in the industry?
Key Attributes:
| The report attribute | Details |
| No. of pages | 137 |
| Forecast period | 2023 – 2032 |
| Estimated market value (USD) in 2023 | 3.6 billion dollars |
| Estimated market value (USD) by 2032 | 7.2 billion dollars |
| Compound annual growth rate | 8.0% |
| Regions covered | overall |
Competitive Landscape:
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Limited
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Serum Institute of India Ltd.
- Walvax Biotechnology Co. Ltd.
Key Market Segmentation:
Breakdown by type of vaccine:
- Conjugate
- Polysaccharide
- Subcapsular
Breakdown by composition:
- Mono Vaccines
- Combined vaccines
Breakdown by vaccine serotype:
- MenACWY
- MenB & Manic
- Mencia
- MenA
- Menace
- Others
Breakdown by distribution channel:
- Hospital Pharmacies
- Retail pharmacies
- Institutional sales
- Others
Breakage by end user:
Breakdown by region:
- north america
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- latin america
- Brazil
- Mexico
- Others
- Middle East and Africa
For more information on this report, visit https://www.researchandmarkets.com/r/ykhe2q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We bring you the latest data on international and regional markets, key industries, top companies, new products and the latest trends.
-
The meningococcal vaccine market
#Billion #Meningococcal #Vaccine #Market #Vaccine #Type #Composition #Vaccine #Serotype #Distribution #Channel #User #Region #Global #Forecast